Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Anil Shanker
School of Medicine, Meharry Medical College 2005 Harold D West Basic Sciences Bldg 1005 Dr DB Todd Jr Blvd,
Nashville, TN 37208
Tanzania
Review Article
Development of Proteasome Inhibitors as Therapeutic Drugs
Author(s): Samuel Troy Pellom Jr. and Anil ShankerSamuel Troy Pellom Jr. and Anil Shanker
The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition presents a promising approach to cancer therapy by targeting the proteasome function in tumor cells. Delineating the success of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma, this review explores various proteasome inhibitors, currently in development, as molecular targeting agents in the fight against cancer. Proteasome inhibitors can be used alone or in combination with other conventional cancer therapies to sensitize tumor cells to cell death by various mechanisms and improve therapeutic benefits... View More»
DOI:
10.4172/2155-9899.S5-005